DURHAM, N.C. (PRWEB) May 02, 2018
Anna D. Krasnodembskaya, Ph.D., has been named STEM CELLS’ Young Investigator of 2017 for her investigations into stem cell-based therapies for acute respiratory distress syndrome (ARDS). The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in STEM CELLS that is deemed to have the most impact and to push the boundaries of novel and insightful research.
Dr. Krasnodembskaya’s award-winning work, published in the August 2016 issue of STEM CELLS, demonstrates for the first time that mitochondria can be transferred from mesenchymal stem cells (MSCs) to innate immune cells via nanotubes, leading to increased activity by macrophages -- a type of white blood cell that rallies to protect the body.
“Nanotubules have been recently discovered to be a fascinating route for cell-to-cell communication. Through them, a mesenchymal stem cell can share its cytoplasmic contents with target cells, even sharing organelles such as mitochondria, which produce nearly all of the chemical energy that cells need to survive. In this excellent new manuscript from the laboratory of young investigator Dr. Anna Krasnodembskaya, nanotubules were the mechanism MSCs used to communicate with macrophages in order to clear bacterial infection in mouse lung,” said Jan Nolta, PhD, Editor-in-Chief of STEM CELLS and director of the University of California Davis Institute for Regenerative Cures.
“As such, the study reveals an important new mechanism by which MSCs improve bacterial clearance in the infected lungs and has important clinical relevance for treating ARDS and other respiratory issues.”
Dr. Krasnodembskaya earned her doctorate in biology at St. Petersburg State University (StPSU), Russia. She was selected to be a member of the StPSU Postdoctoral Fellowship Program and was appointed to an assistant professorship in the Department of Histology and Cytology there. She then conducted her second postdoctoral training at the University of California, San Francisco, in Professor Michael Matthay’s laboratory at the Cardiovascular Research Institute before becoming a Lecturer at Queen’s University of Belfast, UK.
Read the paper that helped Dr. Krasnodembskaya earn the STEM CELLS Young Investigator Award, titled "Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS."
About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.